After Hitting a Speed Bump, Is Rite Aid a Strong Long-Term Play?

Despite higher-than-expected revenue but lackluster profits reported on Jun. 19, shares of Rite Aid fell hard. Is this the time to buy into the business or would Walgreen or CVS be more sensible picks?

Jun 24, 2014 at 2:30PM


Source: Rite Aid

After reporting revenue and earnings for the first quarter of its 2015 fiscal year on Jun. 19, shares of Rite Aid (NYSE:RAD) fell 3.5%. Despite the fact that management reported revenue that exceeded its own expectations, Mr. Market pushed the company's shares down for fear that the drugstore chain won't turn around as quickly as some may have hoped. In light of this share price decline, does Rite Aid present the Foolish investor with some attractive long-term prospects, or would rivals like CVS Caremark (NYSE:CVS) or Walgreen (NASDAQ:WBA) be more appealing plays?

Rite Aid couldn't match expectations
For the quarter, Rite Aid reported revenue of $6.47 billion. In addition to seeing sales come in 3% above the $6.29 billion management reported the same quarter last year, the company's top line results surpassed the $6.43 billion the business anticipated in a Jun. 5 press release. According to the company's earnings release, this rise in sales was driven by a 3.1% improvement in comparable store sales but was negatively affected by a 0.7% reduction in store count to 4,581 locations this year from the 4,614 locations reported this time last year.

  Actual Forecasted Last Year's
Revenue $6.47 billion $6.43 billion $6.29 billion
Earnings per Share $0.04 $0.08 $0.09

Source: Yahoo! Finance

The biggest contributor to Rite Aid's comparable store sales increase came from its pharmacy operations, which rose 4.6% for the quarter, while front-end metrics came in flat. The strong performance in the business's pharmacy operations was attributed to a decent increase in the number of prescriptions filled during the quarter, but was partially offset by more generic introductions, which generally carry lower revenue but higher margins.


Source: Rite Aid

While Rite Aid's top line performance was impressive, the drugstore chain's bottom line was anything but. For the quarter, management reported earnings per share of $0.04, less than half the $0.09 management reported the same quarter a year ago. Even though revenue increased during the quarter, Rite Aid's profitability was negatively affected by rising costs, primarily in its cost of goods sold, which rose from 71.1% of sales to 72.1%.

Can Rite Aid keep up with the competition?
From a revenue standpoint, the past few years have been a wash for Rite Aid. Rite Aid's revenue has been more or less flat over the past five years, moving down from $25.7 billion to $25.5 billion. Now, keep in mind that store count fell by 4% from 4,780 locations to 4,587 as management strove to close underperforming stores. This was, however, mostly offset by an aggregate 0.8% increase in comparable store sales.

In contrast to Rite Aid's poor revenue performance in recent years, both Walgreen and CVS demonstrated their ability to grow rapidly. Between 2009 and 2013, Walgreen grew its sales by 14% from $63.3 billion to $72.2 billion, while CVS's top line skyrocketed by 29% from $98.2 billion to $126.8 billion.

RAD Revenue (Annual) Chart

RAD Revenue (Annual) data by YCharts

From a revenue perspective, Walgreen and CVS trounced Rite Aid during this timeframe. The same cannot be said, however, for their rise in profitability. Between 2009 and 2013, Rite Aid saw its net loss of $506.7 million turn into a net gain of $249.4 million as lower revenue was more than offset by a reduction in costs. During this period, Walgreen's net income jumped 22% from $2 billion to $2.45 billion while CVS's increased 24% from $3.7 billion to $4.6 billion.

Can Rite Aid keep it up?
Moving forward, investors will look not only for improved margins, but will also seek out revenue growth from Rite Aid.  In an effort to grow its operations, management at the retailer has been focused on a few different initiatives aimed toward growing both profitability and market share. 

In 2011, Rite Aid began selling its own private branded items.  Although the company's selling price on these is likely smaller than name brand items, the margins tend to be higher because there's no intermediate party to pay for said products.  Since launching this plan, the company's private brands have grown to represent 18.2% of consolidated sales, which is en par with CVS, which derives 18% of its revenue from private brands.


Source: Rite Aid

Another potentially large growth driver for Rite Aid is its decision to ramp up its Wellness store format development.  In its press release, the company claimed to have 1,325 of its 4,581 stores (or 29% of total stores in operation) already tooled in this manner and it expects to add more moving forward.  By the end of its 2015 fiscal year, Rite Aid plans to turn at least 295 of its stores into Wellness stores, which could help the business's turnaround and might serve as a stronger base from which growth can pick up.

Foolish takeaway
Considering that Rite Aid's bottom line has been growing in recent years and in light of forecasted revenue growth moving forward, it's an interesting investment opportunity.  This is especially true when it's clear that management is dedicated to new innovations that it believes could cause growth to pick up and margins to improve.

However, investing in a turnaround is not without its risks. With such small margins now compared to the margins posted by its peers, any downturn in business could be disastrous for shareholders. For those unwilling to accept these risks, Walgreen and CVS seem to present the Foolish investor with more stable and faster-growing prospects.

Top dividend stocks for the next decade
Aside from the company's less-than-profitable past, there is one other thing Rite Aid is lacking; a strong, stable dividend that could send your portfolio rising for years... maybe even a decade... moving forward!

The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

Daniel Jones has no position in any stocks mentioned. The Motley Fool recommends CVS Caremark. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information